Hancock Holding Co. Increases Stake in Emergent Biosolutions Inc. (EBS)
Hancock Holding Co. increased its position in Emergent Biosolutions Inc. (NYSE:EBS) by 0.5% during the second quarter, Holdings Channel reports. The institutional investor owned 24,130 shares of the biopharmaceutical company’s stock after buying an additional 130 shares during the period. Hancock Holding Co. owned approximately 0.06% of Emergent Biosolutions worth $679,000 at the end of the most recent quarter.
Other institutional investors also recently added to or reduced their stakes in the company. Legal & General Group Plc boosted its position in Emergent Biosolutions by 6.3% in the first quarter. Legal & General Group Plc now owns 4,498 shares of the biopharmaceutical company’s stock worth $162,000 after buying an additional 265 shares in the last quarter. Teacher Retirement System of Texas boosted its position in Emergent Biosolutions by 22.5% in the second quarter. Teacher Retirement System of Texas now owns 4,707 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 866 shares in the last quarter. Springbok Capital Management LLC bought a new position in Emergent Biosolutions during the first quarter worth approximately $192,000. Natixis bought a new position in Emergent Biosolutions during the first quarter worth approximately $205,000. Finally, Meeder Asset Management Inc. bought a new position in Emergent Biosolutions during the first quarter worth approximately $211,000. 91.27% of the stock is owned by institutional investors and hedge funds.
Emergent Biosolutions Inc. (NYSE:EBS) traded up 1.74% during midday trading on Tuesday, reaching $27.46. 123,683 shares of the company were exchanged. Emergent Biosolutions Inc. has a 52 week low of $26.12 and a 52 week high of $44.38. The company has a 50-day moving average of $27.86 and a 200 day moving average of $34.46. The firm has a market capitalization of $1.11 billion, a PE ratio of 19.64 and a beta of 1.24.
Emergent Biosolutions (NYSE:EBS) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by $0.01. Emergent Biosolutions had a return on equity of 11.93% and a net margin of 11.61%. The firm had revenue of $101.49 million for the quarter, compared to the consensus estimate of $111.20 million. During the same quarter in the previous year, the business posted $0.36 EPS. Emergent Biosolutions’s revenue was down 19.5% on a year-over-year basis. Equities analysts predict that Emergent Biosolutions Inc. will post $1.03 earnings per share for the current year.
A number of research firms have commented on EBS. Zacks Investment Research cut shares of Emergent Biosolutions from a “hold” rating to a “sell” rating in a research note on Tuesday, July 12th. Wells Fargo & Co. restated a “buy” rating on shares of Emergent Biosolutions in a report on Wednesday, June 22nd. Singular Research lowered their price objective on shares of Emergent Biosolutions from $44.00 to $40.00 and set a “buy” rating for the company in a report on Tuesday, June 28th. Cowen and Company restated a “hold” rating and issued a $33.00 price objective on shares of Emergent Biosolutions in a report on Sunday, August 7th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Emergent Biosolutions from $45.00 to $36.00 and set an “overweight” rating for the company in a report on Friday, August 5th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $40.00.
About Emergent Biosolutions
Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).
Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc. (NYSE:EBS).
Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.